FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2394947096> ?p ?o ?g. }

• W2394947096 abstract "Most randomised clinical trials typically exclude a significant proportion of asthma patients, including those at higher risk of adverse events, with comorbidities, obesity, poor inhaler technique and adherence, or smokers. However, these patients might differentially benefit from extrafine-particle inhaled corticosteroids (ICS). This matched cohort, database study, compared the effectiveness of extrafine-particle with fine-particle ICS in a real-life population initiating ICS therapy in the Netherlands. Data were from the PHARMO Database Network, comprising pharmacy and hospital discharge records, representative of 20 % of the Dutch population. The study population included patients aged 12 − 60, with a General Practice-recorded diagnosis for asthma (International Classification of Primary Care code R96), when available, ≥2 prescriptions for asthma therapy at any time in their recorded history, and receiving first prescription of ICS therapy as either extrafine-particle (ciclesonide or hydrofluoroalkane beclomethasone dipropionate [BDP]) or fine-particle ICS (fluticasone propionate or non-extrafine-particle-BDP). Patients were matched (1:1) on relevant demographic and clinical characteristics over 1-year baseline. Primary outcomes were severe exacerbation rates, risk domain asthma control and overall asthma control during the year following first ICS prescription. Secondary outcomes, treatment stability and being prescribed higher versus lower category of short-acting β2 agonists (SABA) dose, were compared over a 1-year outcome period using conditional logistic regression models. Following matching, 1399 patients were selected in each treatment cohort (median age: 43 years; males: 34 %). Median (interquartile range) initial ICS doses (fluticasone-equivalents in μg) were 160 (160 − 320) for extrafine-particle versus 500 (250 − 500) for fine-particle ICS (p < 0.001). Following adjustment for residual confounders, matched patients prescribed extrafine-particle ICS had significantly lower rates of exacerbations (adjusted rate ratio [95 % CI], 0.59 [0.47–0.73]), and significantly higher odds of achieving asthma control and treatment stability in the year following initiation than those prescribed fine-particle ICS, and this occurred at lower prescribed doses. Patients prescribed extrafine-particle ICS had lower odds of being prescribed higher doses of SABA (0.50 [0.44–0.57]). In this historical, matched study, extrafine-particle ICS was associated with better odds of asthma control than fine-particle ICS in patients prescribed their first ICS therapy in the Netherlands. Of importance, this was reached at significantly lower prescribed dose." @default.
• W2394947096 created "2016-06-24" @default.
• W2394947096 creator A5017944102 @default.
• W2394947096 creator A5022426905 @default.
• W2394947096 creator A5030603878 @default.
• W2394947096 creator A5031762844 @default.
• W2394947096 creator A5033749081 @default.
• W2394947096 creator A5035054463 @default.
• W2394947096 creator A5036290773 @default.
• W2394947096 creator A5044705183 @default.
• W2394947096 creator A5046059982 @default.
• W2394947096 creator A5046225789 @default.
• W2394947096 creator A5052175038 @default.
• W2394947096 creator A5052181934 @default.
• W2394947096 creator A5071030647 @default.
• W2394947096 creator A5076342582 @default.
• W2394947096 creator A5091663221 @default.
• W2394947096 date "2016-05-17" @default.
• W2394947096 modified "2023-10-09" @default.
• W2394947096 title "Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands" @default.
• W2394947096 cites W1964815067 @default.
• W2394947096 cites W1985228166 @default.
• W2394947096 cites W2010818576 @default.
• W2394947096 cites W2014230465 @default.
• W2394947096 cites W2017385258 @default.
• W2394947096 cites W2019258544 @default.
• W2394947096 cites W2021023200 @default.
• W2394947096 cites W2029536496 @default.
• W2394947096 cites W2035216610 @default.
• W2394947096 cites W2042693868 @default.
• W2394947096 cites W2058979515 @default.
• W2394947096 cites W2068523761 @default.
• W2394947096 cites W2080725789 @default.
• W2394947096 cites W2100630414 @default.
• W2394947096 cites W2114547039 @default.
• W2394947096 cites W2141225625 @default.
• W2394947096 cites W2155163959 @default.
• W2394947096 cites W2170637423 @default.
• W2394947096 doi "https://doi.org/10.1186/s12890-016-0234-0" @default.
• W2394947096 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4958282" @default.
• W2394947096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27450521" @default.
• W2394947096 hasPublicationYear "2016" @default.
• W2394947096 type Work @default.
• W2394947096 sameAs 2394947096 @default.
• W2394947096 citedByCount "15" @default.
• W2394947096 countsByYear W23949470962016 @default.
• W2394947096 countsByYear W23949470962017 @default.
• W2394947096 countsByYear W23949470962018 @default.
• W2394947096 countsByYear W23949470962019 @default.
• W2394947096 countsByYear W23949470962020 @default.
• W2394947096 countsByYear W23949470962021 @default.
• W2394947096 countsByYear W23949470962022 @default.
• W2394947096 crossrefType "journal-article" @default.
• W2394947096 hasAuthorship W2394947096A5017944102 @default.
• W2394947096 hasAuthorship W2394947096A5022426905 @default.
• W2394947096 hasAuthorship W2394947096A5030603878 @default.
• W2394947096 hasAuthorship W2394947096A5031762844 @default.
• W2394947096 hasAuthorship W2394947096A5033749081 @default.
• W2394947096 hasAuthorship W2394947096A5035054463 @default.
• W2394947096 hasAuthorship W2394947096A5036290773 @default.
• W2394947096 hasAuthorship W2394947096A5044705183 @default.
• W2394947096 hasAuthorship W2394947096A5046059982 @default.
• W2394947096 hasAuthorship W2394947096A5046225789 @default.
• W2394947096 hasAuthorship W2394947096A5052175038 @default.
• W2394947096 hasAuthorship W2394947096A5052181934 @default.
• W2394947096 hasAuthorship W2394947096A5071030647 @default.
• W2394947096 hasAuthorship W2394947096A5076342582 @default.
• W2394947096 hasAuthorship W2394947096A5091663221 @default.
• W2394947096 hasBestOaLocation W23949470961 @default.
• W2394947096 hasConcept C119060515 @default.
• W2394947096 hasConcept C126322002 @default.
• W2394947096 hasConcept C187212893 @default.
• W2394947096 hasConcept C2776042228 @default.
• W2394947096 hasConcept C2779028295 @default.
• W2394947096 hasConcept C2781212218 @default.
• W2394947096 hasConcept C2908647359 @default.
• W2394947096 hasConcept C71924100 @default.
• W2394947096 hasConcept C72563966 @default.
• W2394947096 hasConcept C99454951 @default.
• W2394947096 hasConceptScore W2394947096C119060515 @default.
• W2394947096 hasConceptScore W2394947096C126322002 @default.
• W2394947096 hasConceptScore W2394947096C187212893 @default.
• W2394947096 hasConceptScore W2394947096C2776042228 @default.
• W2394947096 hasConceptScore W2394947096C2779028295 @default.
• W2394947096 hasConceptScore W2394947096C2781212218 @default.
• W2394947096 hasConceptScore W2394947096C2908647359 @default.
• W2394947096 hasConceptScore W2394947096C71924100 @default.
• W2394947096 hasConceptScore W2394947096C72563966 @default.
• W2394947096 hasConceptScore W2394947096C99454951 @default.
• W2394947096 hasIssue "1" @default.
• W2394947096 hasLocation W23949470961 @default.
• W2394947096 hasLocation W23949470962 @default.
• W2394947096 hasLocation W23949470963 @default.
• W2394947096 hasLocation W23949470964 @default.
• W2394947096 hasLocation W23949470965 @default.
• W2394947096 hasLocation W23949470966 @default.
• W2394947096 hasLocation W23949470967 @default.
• W2394947096 hasLocation W23949470968 @default.
• W2394947096 hasOpenAccess W2394947096 @default.
• W2394947096 hasPrimaryLocation W23949470961 @default.

• next